SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

IPIX Clinical Trial Timelines

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
sox040713 Member Profile
 
Followed By 43
Posts 4,654
Boards Moderated 1
Alias Born 11/04/11
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) "Edgar (US Regulatory)" - 11/13/2017 10:03:05 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/8/2017 4:04:57 PM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 9/22/2017 6:02:17 AM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 9/11/2017 12:47:10 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 9/11/2017 6:04:38 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/11/2017 6:04:37 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/6/2017 6:27:18 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/6/2017 6:24:45 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 8/8/2017 4:18:08 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:17:33 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:17:00 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:16:36 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/13/2017 4:04:10 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/7/2017 4:19:05 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/9/2017 4:09:09 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 4/28/2017 12:50:45 PM
Bahamas Development Corp. (OTC Pink: BDCI) $2.4 Million in Sales and 10% Quarterly Growth – Issues Guidance "InvestorsHub NewsWire" - 4/17/2017 7:03:27 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/31/2017 4:25:24 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 3/29/2017 4:13:08 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/27/2017 11:29:27 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/16/2017 7:01:38 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 2/9/2017 4:04:17 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/9/2017 9:39:24 AM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 1/4/2017 3:58:28 PM
sox040713   Saturday, 10/14/17 08:13:18 PM
Re: None
Post # of 207478 
IPIX Clinical Trial Timelines

2012
1. Kevetrin (Phase 1)

2013
1. Kevetrin (Phase 1)

2014
1. Kevetrin (Phase 1)
2. Brilacidin-ABSSSI (Phase 2b)
3. Prurisol (Phase 1)

2015
1. Kevetrin (Phase 1)
2. Brilacidin-ABSSSI (Phase 2b, Successful)
3. Prurisol (Phase 1, Successful)
4. Brilacidin-OM (Phase 2)
5. Prurisol (Phase 2a)

2016
1. Kevetrin (Phase 1, Successful)
2. Brilacidin-ABSSSI (Phase 2b, Successful)
3. Prurisol (Phase 1, Successful)
4. Brilacidin-OM (Phase 2)
5. Prurisol (Phase 2a, Successful)
6. Brilacidin-UP (Phase 2 POC)
7. Prurisol (Phase 2b)

2017
1. Kevetrin (Phase 1, Successful)
2. Brilacidin-ABSSSI (Phase 2b, Successful)
3. Prurisol (Phase 1, Successful)
4. Brilacidin-OM (Phase 2)
5. Prurisol (Phase 2a, Successful)
6. Brilacidin-UP (Phase 2 POC, Successful)
7. Prurisol (Phase 2b)
8. Kevetrin-OC (Phase 2a)

https://clinicaltrials.gov/ct2/results?term=cellceutix&Search=Search




FUD - Fear, uncertainty and doubt, is generally a strategic attempt to influence perception by disseminating negative and dubious or false information.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist